Kidney transplant outcomes in patients with complement dysregulation. (PubMed, World J Transplant) - Sep 18, 2026 - "In this Indian transplant cohort with complement dysregulation, CFHR1-CFHR3 structural variants and AFH antibody positivity defined the predominant biologic substrate, post-transplant recurrence clustered within the early weeks after transplantation, and disease-directed therapy with plasma exchange, rituximab, and selective eculizumab achieved durable graft preservation despite limited access to long-term complement inhibition. Comprehensive pre-transplant complement evaluation and biologic risk stratification are essential for safe transplantation in complement-mediated kidney disease, particularly in resource-limited settings."
Journal • Atypical Hemolytic Uremic Syndrome • Cardiovascular • Complement-mediated Rare Disorders • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Nephrology • Transplantation • CD46 • CFHR3
|
|
Amit Pasari; Kapil Sejpal; Manish Balwani; Mohit Kurundwadkar; Nishtha Manuja; Pranjal Kashiv; Priyanka Tolani; Shubham Dubey; Sunny Malde; Sushrut Gupta; Twinkle Pawar; Vijay Jeyachandran; Vishal Ramteke; Vivek B Kute
|